Three-Drug Breast Cancer Regimen Slows Progression

In a Phase II randomized trial, investigators compared an aromatase inhibitor (AI) combined with pertuzumab (Perjeta) and trastuzumab (Herceptin) versus an AI just with trastuzumab in women with locally advanced or metastatic breast cancer, Grazia Arpino, MD, PhD, of the University of Naples Federico II in Italy, reported at a general session at the San Antonio Breast Cancer Symposium.

The three-drug combination led to a median of 18.89 months without progression, compared with 15.8 months for the two drugs.

To read more go to :

medpagetoday.com/MeetingCov...

oldestnewest

You may also like...